Tech Company Financing Transactions
Interon Laboratories Funding Round
Interon Laboratories closed a funding round on 2/10/2023. Investors included HanAII Biopharma.
Transaction Overview
Company Name
Announced On
2/10/2023
Transaction Type
Amount
Unknown
Round
Undisclosed
Investors
HanAII Biopharma (Lead Investor)
Proceeds Purpose
The investment will fund Interon's continued development of its lead programs targeting an array of neurological and immune disorders.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
90 Bridge St
Newton, MA 02458
USA
Newton, MA 02458
USA
Phone
Undisclosed
Website
Email Address
Overview
Interon Laboratories is developing a new category of immunotherapy: neuro-immunotherapy. Interon's exclusive technology brings together neurobiology and immunology, and is novel and non-invasive. This revolutionary science includes discoveries made by Interon's Co-Founders at MIT and Harvard Medical School, and was featured in journals including Nature, Science and Cell. Additionally, Interon has two lead programs to develop biologics and small molecule therapeutics for mitigating neurological and immune disorders.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Sean Jeong
Browse more venture capital transactions:
Prev: 2/10/2023: Flawless venture capital transaction
Next: 2/10/2023: Wikifarmer venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on all VC transactions involving tech companies. VC investment data records reported here come from publicly available VC deal announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs